Last reviewed · How we verify

NCT05090345

A Prospective Registry of Pediatric Cellular Therapy Patients at Risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS).

Recruiting now Last updated 20 April 2025
What this trial tests

trial testing Biorepository Trial in Hematopoietic Cell Transplantation in 500 participants. Currently enrolling.

Timeline
19 November 2019
Primary endpoint
5 February 2026
5 February 2026

Quick facts

Lead sponsorDuke University
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment500
Start date19 November 2019
Primary completion5 February 2026
Estimated completion5 February 2026
Sites3 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Duke University

Who can join

Adults 0 to 26, any sex, with Hematopoietic Cell Transplantation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective international multi-center registry and biorepository trial of children and adolescents/young adults (AYA) undergoing hematopoietic cell transplantation (HCT) to assess the impact of endotheliopathies in the HCT setting as a contributor of significant morbidity and mortality.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hematopoietic Cell Transplantation

Currently open trials in the same condition.

Other Duke University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05090345.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing